PIK3CD and posterior cortical atrophy: Hence, in this complex scenario focused on identifying both disease biomarkers and novel and effective treatments that will benefit patients with PCa, this review centers on the current scene of different Phosphatidylinositol-3-kinase (PI3K) signaling pathway inhibitors, either as monotherapy or in combination treatments in PCa, and the treatment outcomes involved in both preclinical and clinical trials.